Introduction
Respiratory syncytial virus (RSV) is a member of the Paramyxoviridae family and results in approximately 55 adult hospitalizations per 100,000 person years. 1 In healthy adults, RSV typically manifests as an upper respiratory tract infection (URTI) with patients experiencing rhinorrhea, pharyngitis, sinusitis, and cough. Treatment consists of supportive care, typically in the outpatient setting.
In contrast, elderly and immunocompromised patients may progress from an URTI to a lower respiratory tract infection (LRTI) with symptoms ranging from dyspnea and/or chest tightness, to acute respiratory distress syndrome and respiratory failure. The availability of rapid diagnostic tests, including the multiplex polymerase chain reaction (PCR) test, has increased the identification of RSV as a source of pulmonary infections. 2 Treatment of RSV may be necessary in patients with impaired cellular immunity, since the ability to contain and eradicate RSV is reduced. Severely immunocompromised populations such as bone marrow transplant recipients (BMT), hematopoietic stem cell transplant recipients (HSCT), neutropenic patients, solid organ transplant recipients (SOT), and patients with human immunodeficiency virus (HIV) have a risk of mortality from RSV as high as 80%. 3 In addition, RSV infections in lung transplant recipients may increase the risk of chronic rejection. 4 Despite the high mortality and morbidity associated with RSV infections in immunocompromised patients, there remains a lack of prospective, randomized trials to help guide clinicians on appropriate management of LRTI in hospitalized adults.
Current treatment options for RSV LRTI include aerosolized or oral ribavirin (RBV) in combination with palivizumab (PZB), corticosteroids, and/or intravenous immunoglobulin (IVIG).
Aerosolized ribavirin (RBV AER) was approved by the Food and Drug Administration (FDA) in 1985 for the treatment of RSV in hospitalized pediatric patients. [5] [6] Therapy may only be administered via the small particle aerosol generator which produces particles in the range of 1.0 to 1.3 µm to ensure adequate concentrations in the lower respiratory tract. 7 Safety concerns of RBV AER include bronchospasm and dyspnea; furthermore, healthcare workers and visitors must be aware of potential teratogenic effects.
Additionally, cost of RBV AER has risen dramatically since FDA approval, with most recent estimates of an average wholesale price (AWP) of nearly $120,000 U.S. dollars (USD) for four-6g vials and $10,000 less for the generic. 8 Drug administration barriers, including high acquisition cost, and lack of controlled trials has made use of RBV AER for treatment of RSV LRTI in hospitalized adults with immunocompromising conditions challenging. 9 The decision to initiate therapy is even more difficult when immunocompromised patients present with RSV LRTI to a non-transplant community hospitals which might not have established protocols like transplant or oncology centers. The purpose of this systematic review is to summarize the efficacy and adverse drug event (ADE) profile of RBV AER for the treatment of RSV LRTI in adult immunocompromised patients.
Methods
Study design and data source , Clinicaltrials.gov, The Cochrane Library (no date limit performed on) and Google Scholar (no date limit performed on). Search terms included "ribavirin", "ICN 1229", "administration, inhaled" or "inhalation", "administration, oral" or "oral", "respiratory syncytial virus", "drug therapy", "pneumonia", "respiratory tract infection", "respiratory syncytial virus infections/drug therapy. Example search strategy for Pubmed: Search strategy: [(ribavirin OR ICN 1229) AND ("administration, oral" OR "oral" OR "administration, inhalation" OR "inhalation")] AND ("respiratory tract infection" OR "pneumonia")
Additional references were identified from records in the original search, the National Comprehensive Cancer Network (NCCN) Guidelines, and the FDA database Drugs@FDA.
Inclusion/Exclusion Criteria
Inclusion criteria was based upon the PICOS method and records meeting all of the following criteria were included in the qualitative analysis. 10 Patient population was defined as immunocompromised hospitalized adults ≥ 18 years old with HSCT or BMT, other malignancy, neutropenia (absolute neutrophil count (ANC) ≤ 500 neutrophils/mL), SOT, HIV, chronic corticosteroid use defined as greater than 10mg of prednisone or equivalent per day, 11 or receipt of maintenance immunosuppressant(s).
Patients must also have a documented RSV infection of the lower respiratory tract or RSV pneumonia.
Intervention criteria included treatment with RBV AER alone or in combination with other therapies.
Studies were included whether or not comparison to oral or intravenous RBV or other drug therapies occurred. To meet inclusion criteria, studies must have reported at least one of the following outcome measures: in-hospital mortality, 30-day all-cause mortality, or RSV-mortality defined by autopsy, or change in pulmonary function as defined in the manuscript. If specific mortality was not stated, it was assumed to be in-hospital mortality. Post hoc, the decision was made to include the occurrence of obstructive bronchiolitis (OB) or bronchiolitis obliterans syndrome (BOS) as an outcome in lung transplant recipients. All observational studies and controlled trials, retrospective or prospective, meeting all or any of the above criteria were included. Reviews and foreign language publications were excluded.
When outcomes were inseparable for mixed populations the study was excluded. For example, studies reporting adult and pediatric population outcomes were excluded if the adult outcomes were not reported 
Search results
A total of 1,787 records were identified. The Google Scholar search comprised 75% of the records (1, 350) . The PRISMA flow diagram is located in Figure 1 . 10 This qualitative review includes 15 publications meeting inclusion criteria; thirteen identified in the original systematic search and 2 identified via the updated PubMed search. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] All of the trials are observational and begin with a low quality rating. No trials meet criteria for upgrading to moderate or high quality, including the three prospective trials. 14,,22,25 No articles were identified that met the inclusion criteria for patients with HIV, receiving chronic corticosteroids, or maintenance immunosuppressant therapies. Based on the lack of randomized trials, lack of comparative groups, and heterogeneity of the study population a narrative review was prepared.
Oncology HSCT/BMT patients A total of 163 cases of RSV LRTI were reported in 8 articles (Table 1) , [13] [14] [15] [16] [17] [18] [19] [20] Peck et al performed an observational study that included all HSCT candidates who had positive RSV surveillance testing prior to BMT. 19 There were 37 pediatric and adult patients who were diagnosed with RSV URTI prior to transplant. Of these patients, 3 adults were diagnosed after the start of cyclophosphamide and total body irradiation conditioning regimen, and were transplanted. RSV for RBV AER and RBV PO respectively; separate data was not reported. In addition, patients did not receive concomitant immunoglobulin therapy. There was no difference in 30-day mortality in patients treated with RBV PO and RBV AER 4/29 (13.8%) and 6/39 (15.4%), p=1.0. The authors did not comment on the 4 patients that were not included in the mortality analysis. Length of stay, transfer to the intensive care unit, and mechanical ventilation was reported for both URTI and LRTI population, but was not stratified to the LRTI population.
Other malignancy or neutropenic patients (ANC ≤ 500 neutrophils/mL)
A total 33 cases of RSV LRTI occurring in oncology/neutropenic patients who received RBV AER were reported in 2 articles (Table 2 ) published in 1995 and 2014. 21, 22 The articles were classified as low or very low quality. All participants had a diagnosis of leukemia and did not undergo a BMT/HSCT. Of the 33 cases, 22 received RBV AER and 11 were not treated. RBV AER dosing regimens varied from 2g over 2 to 3 h every 8 h to 6g aerosolized over 18 h daily. Duration of RBV AER therapy ranged from 2 to 36 days. Combination therapy with IVIG was documented in 6 patients and 16 patients received either monotherapy or combination therapy with IVIG or PZB. One article addressed early versus late treatment outcomes in MV patients. 22 Torres et al performed a retrospective cohort study of leukemic patients with evidence of RSV identified by the microbiology laboratory. 21 Of 52 patients identified, 45 were admitted to the hospital and 27
patients were diagnosed with a LRTI. Of those with a LRTI, 26% were admitted to the ICU, the median APACHE II score was 16 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , and the median length of hospital stay was 12 days. A total of 16 patients received RBV AER either as monotherapy or in combination with IVIG or PZB. RBV AER was initiated a median of 1 day (1-12) from RSV diagnosis. The 30 day mortality rate was 6.3% (1/16) compared to 36% (4/11) in the no treatment group (p=0.1).
Whimbey et al performed a prospective cohort study to determine outcomes of all adult leukemia patients who were hospitalized with an acute respiratory illness and RSV was identified by culture. 22 A total of 6 patients presented with LRTI, neutropenia and lymphopenia and received treatment with RBV AER in combination with IVIG. The duration of therapy was individualized at the discretion of the prescriber, based on illness severity, clinical response, and time to recovery from neutropenia. In-hospital mortality was 83% (5/6). All 4 patients who were initiated on RBV AER within 24 h of mechanical ventilation died. The sole survivor received early treatment when the FIO2 was 35% with a low supplemental oxygen requirement.
Solid organ transplant recipients (SOT)
A total 65 cases of RSV LRTI were reported in 4 articles (Table 3) 23-26 , published from 1998-2012 in adult SOT patients. One study included 36 immunocompromised patients with approximately 50% lung transplant patients. 27 All studies were classified as low or very low quality. Zamora et al was designed
with case match comparators which may increase its quality rating, but since it was published only as an abstract, a full quality analysis could not be completed. 25 The majority of patients were lung or heart-lung recipients. Of the 101 cases, 76 were initiated on RBV AER and 23 on RBV PO. A single patient received RBV AER with transition to RBV PO and 2 were not treated. RBV AER dosing regimens varied from 2g every 8 h to 6g over 12 or 18 h daily. Duration of RBV AER therapy ranged from 3 to 30 days.
Early versus late treatment outcome was addressed in one study 25 and 2 studies reported outcomes with MV. 23, 24 BOS/OB was addressed in 3 studies. 24, 25, 26 Ariza et al performed a retrospective cohort study of adult and pediatric SOT patients hospitalized with RSV during 2007 to 2009. 23 Of 263 cases, only 8 adult patients with RSV LRTI were identified.
Transplants included lung (n=2), kidney (n=2), kidney/pancreas (n=1), and liver (n=3). Lymphocyte Zamora et al in a prospective case control study evaluated 30 day mortality and incidence of BOS in 44 lung transplant patients receiving RBV AER monotherapy or combination with PZB, RSV IVIG, or IVIG. 25 This study found a statistically significant lower 30 day mortality (0% vs 27%) and incidence of BOS (21% vs 100%) in the early treatment group, defined as less than 2 weeks post symptom onset. This was in abstract form and the patients treated greater than 2 weeks post symptom onset were not clearly delineated.
Li et al performed a retrospective cohort of adult lung or heart/lung transplant patients from 2006 to 2010 with the primary outcome to compare the use of RBV AER and RBV PO on the incidence of BOS progression in RSV infected patients. 26 Included patients had to be at least 30 days from transplant and were excluded if survival was less than 6 months. Treatment was determined by prescriber preference. A total of 19 patients were included in the analysis; 12 patients with LRTI were treated with RBV AER (4 patients) or RBV PO (8 patients). Only 4 of the 8 patients treated with RBV PO were hospitalized.
Severe disease, defined as the need for MV, was present in 1 and 2 patients in the RBV AER and RBV PO groups, respectively. Hospital and 30 day mortality was 0% (0/8). Hospital length of stay (including URTI) with RBV AER and RBV PO was 11 ± 15.1 and 5 ± 1.5 days, respectively (p=0.37). The primary outcome of BOS included both patients with upper and LRTI. Infection severity was defined by oxygen requirement and was similar in both groups. A total of 3 of 15 patients who received RBV AER at baseline had BOS 1 or greater at the time of infection and 2 patients progressed or developed new onset BOS at 6 months follow up. There were no cases of BOS in the 6 patients who received RBV PO.
Trang et al performed a retrospective cohort study from 2013 to 2016 on adult patients who received either RBV AER or RBV PO for the treatment of RSV infections in the outpatient or inpatient setting. There were 5 patients who required an increase in supplemental oxygen in the RBV AER group and 2 patients in the RBV PO group. None of the patients in either group required mechanical ventilation.
Adverse drug events
Documentation of ADEs were available in 5 of the 15 studies reviewed. 14, 22, 23, 26, 27 ADEs related to RBV AER included psychiatric manifestations (anxiety, depression, feeling of isolation; n = 14), wheezing (n = 4), bronchospasm (n=2) snowflakes/hail blowing in face (n = 6), and precipitation in ventilator tubing (n = 5). There were 2 patients that developed anemia after receiving RBV PO, one requiring a blood transfusion. One patient on RBV PO developed thrombocytopenia and a decrease in absolute lymphocyte count. Nausea was reported in 6 patients, but did not state whether the patients were on RBV AER or RBV PO.
Discussion
This systematic review was designed to review the outcomes in-hospital mortality and ADEs to help practitioners decide whether to initiate RBV AER for treatment of RSV LRTI in hospitalized adult immunocompromised patients. An extensive literature search revealed an absence of randomized clinical trials to provide quality evidence. The reviewed trials span from 1987 to 2017 and utilize different dosing regimens, durations, timing from diagnosis, and diagnostic methods to detect RSV disease. It was also difficult to discern population data on patients with LRTI, since a majority of studies included data on both URTI and LRTI. In this systematic review 4 trials present mortality as a function of timing of RBV AER therapy and the authors report a mortality benefit. 13, 14, 22, 25 The efficacy of this treatment modality appears to be decreased if the therapy is initiated after the start of MV. This may be related, to problems with administration of RBV AER in patients on MV or severity of illness. Patient isolation and the resulting psychological effects must be weighed against the benefit of therapy.
Currently, there are no published systematic reviews that evaluate the use of RBV AER for LRTI in the adult immunocompromised population. A recent 2 year observational study reported a 30 day mortality rate in HSCT/SOT, immunocompromised non-transplant patients, and chronic obstructive pulmonary disease patients of 5.8%, 4.2%, and 10.3%. 28 This study did not differentiate between URTI, LRTI, or RBV route of administration. Shah et al published a review in HSCT patients with LRTI and reported a RSV mortality of 24% in patients receiving RBV AER combination therapy. 29 The definition of RSV mortality was not based on autopsy results. It is difficult to compare mortality amongst the studies reviewed since most studies contained less than 10 patients with LRTI treated with RBV AER. The 30-day mortality in studies that contain more than 10 patients with HSCT, malignancy, and transplant range from 0% to 15.4%, 6.3%, and 0% to 27% respectively. 15, 16, 17, 20, 21, 25, 27 The paucity of comparative data was evident in this review. Of the observational studies reviewed, only 3 studies compared RBV AER to RBV PO in the immunocompromised population. 20, 23, 27 The ease of use and decreased cost of RBV PO makes it an attractive therapeutic option, although there is very limited data to show improved efficacy over RBV AER. A systematic review of RBV PO in non-influenza respiratory viral infections reported a mortality ranging from 0-31% and 10-20% in both the HSCT and the lung transplant population. 30 A direct comparison cannot be made with RBV AER since the population studied included both URTI and LRTI and the severity of illness varied amongst populations.
The time from diagnosis to the initiation of RBV AER varied widely. In the trials that presented mortality data based on late initiation in relationship to diagnosis or mechanical ventilation the mortality rates were 27% (3/11) and 100% (9/9) respectively. 13, 14 Based on these results, prompt diagnosis of RSV LRTI and initiation of RBV AER may improve outcomes. Nevertheless, there may be a time point when the use of RBV AER may not be effective; including patients who develop respiratory failure and are intubated.
Some authors hypothesize that this may be due to a decrease in the amount of ribavirin able to penetrate the lower lung during ventilation or possibly from the amount of ribavirin that coats the ventilator circuit tubing. 6 Only 5 studies commented on the occurrence of ADEs in patients receiving RBV AER. 14, 22, 23, 26, 27 In studies that reported ADE, the majority were psychiatric in nature. Drug administration via use of a face mask inside a double-tent scavenger system for up to 18 h per day causes the patient to experience prolonged isolation. Clinicians must consider the psychological effects of therapy including loneliness, anxiety and depression. Wheezing and bronchospasm were documented in 6 patients, although it is difficult to determine if the wheezing was a result of RSV LRTI or RBV AER effect on airway resistance.
Healthcare workers and patients should be educated on the potential teratogenic risks, as well as nasal, pharyngeal, bronchial, and/or eye irritation during RBV AER exposure. 31 Lastly, RBV AER led to precipitation in the ventilator circuit in 5 events. It is important that respiratory policy and procedures are in place before RBV AER therapy is administered. Respiratory therapists must be trained on the appropriate administration technique, since it may vary with specific ventilator types.
Guidance for the treatment of RSV LRTI in adults is available from national and international stakeholders including the Infectious Diseases Society of America (IDSA), whom do not recommend antiviral therapy due to the lack of proven value. 32 In 2013, the Fourth European Conference on
Infections in Leukemia (ECIL-4) guidelines were published and recommend treating RSV LRTI with RBV AER [2g over 2 h every 8 h or 6g over 18 h per day for 7-10 days (BII recommendation)] plus IVIG given previous studies suggesting improved outcomes. Oral RBV and intravenous RBV have weaker quality of evidence and strengths of recommendation (BIII and CIII, respectively). 33 The 2018 per day (6g vial). 35 In 1994, the cost increased to over $1,000 USD AWP per day of therapy, and is currently nearing $30,000 USD AWP daily. 8, 36 The introduction of the generic product and hospital purchasing contracts may result in lower drug acquisition cost. These figures simply represent drug costs, and do not include the indirect costs related to the isolation room, drug administration, and nursing and respiratory therapist support. There are new antiviral agents being studied for RSV infection including fusion inhibitors, nucleoside analogues and non-nucleoside polymerase inhibitors, but none are currently FDA approved. 37, 38 Limitations
The limitations of this study are a result of the many limitations present in the included studies, including small sample size, minimal patient demographics, limited information on duration of administered RBV AER and administration of additional therapies that overall confounds the results. Although not calculated due to the lack of studies with comparator groups, it is evident that there is heterogeneity amongst the different trials and patient populations. It is also difficult to ascertain the cause of mortality in this high risk population when there are other potential causes for mortality including concomitant bacterial pathogens and underlying comorbidities. Some studies included in this systematic review were performed in the 1980's and the diagnosis of RSV was confirmed by viral culture, since then there have been significant advances with rapid diagnostic testing for RSV disease that should improve time to diagnosis and treatment. In addition, there was some variability in the definition of LRTI and pneumonia in the studies.
Conclusion
There is a lack of comparative trials on the use of RBV AER for the treatment of RSV LRTI in adult hospitalized immunocompromised patients. This systematic review only identified studies in the HSCT/BMT, leukemic, and transplant population. Dosing regimens ranged from 2g over 2-3h every 8h
to 6g over 12-18h daily with no standardized durations. No conclusions can be made on the mortality benefit with combination therapy (IVIG and or PZB).There may be a mortality benefit when RBV AER is initiated early after the diagnosis or prior to MV, although this warrants further study. Patient isolation and the resulting psychological effects must be weighed against the benefit of therapy.
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